If a provider told you to just lose weight before trying to conceive without asking about your eating patterns, your cycle, or your relationship with food (and dont get me started on the lack of eating disorder screening), thats not evidence-based care
Retrieved 14 May 2022, from A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE)
It means the next step should be based on response, goals and overall health not a rigid sequence
J., Wu, Q., Lalonde, A., Ahmad, N., & Bethel, M
The samples were run with a Bio-Rad CFX96 Real-time PCR system with a reverse transcription reaction for 10 min at 50 C, polymerase activation and DNA denaturation for 1 min at 95 C followed by 39 cycles of amplification (denaturation for 10 s at 95 C, annealing/extension for 15 s at 60 C) and a melt-curve analysis at 6595 C in 0.5 C increments
90% of patients experienced noticeable weight loss within the first 3 months 93% of patients reported increased activity levels and stamina after 2 months 79% of patients saw an increase in their enjoyment of life after 6 months 87% of patients achieved significant improvements in metabolic health markers after 6 months 86% of patients saw an improvement in their energy levels after 3 months 96% of patients saw an improvement in their mood after 3 months 94% of patients were satisfied with the treatment they received CITATIONS Based on data on Layla clinical care data of over 1000 patientes over the last 12 months